Cargando…

Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues

Renal cell carcinoma is one of the most common urological tumors. The role of programmed cell death 1 ligand 1 (PD-L1) in renal cell carcinomas in predicting outcome of the patients is yet unclear. We analyzed the clinical and RNA-seq data of 522 kidney clear cell cancer, 259 kidney papillary cell c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ning, Xiang-hui, Gong, Yan-qing, He, Shi-ming, Li, Teng, Wang, Jiang-yi, Peng, Shuang-he, Chen, Jin-chao, Liu, Jia-yuan, Qi, Nie-nie, Guo, Ying-lu, Gong, Kan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356887/ https://www.ncbi.nlm.nih.gov/pubmed/27926518 http://dx.doi.org/10.18632/oncotarget.13765

Ejemplares similares

Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
por: Zhu, Jun, et al.
Publicado: (2017)

Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer: A Meta-Analysis
por: Zhang, Yaxiong, et al.
Publicado: (2015)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Downregulation of lncRNA APCDD1L-AS1 due to DNA hypermethylation and loss of VHL protein expression promotes the progression of clear cell renal cell carcinoma
por: Yang, Wuping, et al.
Publicado: (2022)

Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis
por: Li, Yifan, et al.
Publicado: (2018)

AB180. The relationship between fructose-1, 6-bisphosphatase and hypoxia related genes expression in clear cell renal cell carcinoma
por: Ning, Xianghui, et al.
Publicado: (2015)

Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma
por: Chipollini, Juan, et al.
Publicado: (2018)

The combination of NDUFS1 with CD4(+) T cell infiltration predicts favorable prognosis in kidney renal clear cell carcinoma
por: Wu, Dong, et al.
Publicado: (2023)

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics
por: Abaza, Abdelrahman, et al.
Publicado: (2023)

Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1
por: Yang, Wuping, et al.
Publicado: (2021)

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
por: Li, Yaqi, et al.
Publicado: (2016)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
por: Drakes, Maureen L., et al.
Publicado: (2018)

Correction to: Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1
por: Yang, Wuping, et al.
Publicado: (2021)

Orai1 Expression Is Closely Related with Favorable Prognostic Factors in Clear Cell Renal Cell Carcinoma
por: Lkhagvadorj, Sayamaa, et al.
Publicado: (2016)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
por: Spirina, Liudmila, et al.
Publicado: (2021)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

Clinical significance of programmed death‐1 and programmed death‐ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma
por: Mikami, Shuji, et al.
Publicado: (2019)

Retraction Note: Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)- methyladenosine modification of MT-RNR1
por: Yang, Wuping, et al.
Publicado: (2023)

Programmed cell death 1 ligand (PD-L1) on T cells generates Treg suppression from memory
por: Kazanova, Alexandra, et al.
Publicado: (2021)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer
por: Baş, Yılmaz, et al.
Publicado: (2020)

Association Between Activation of the Programmed Cell Death-1 (PD-1)/Programmed Death-Ligand 1 (PD-L1) Pathway and Pain in Patients with Cancer
por: Zhang, Jian, et al.
Publicado: (2019)

Concordance of PD‐1 and PD‐L1 (B7‐H1) in paired primary and metastatic clear cell renal cell carcinoma
por: Eckel‐Passow, Jeanette E., et al.
Publicado: (2019)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

Expression of programmed death (PD)-1 and PD-1 ligands (PD-L1, PD-L2) in peripheral blood mononuclear cells of patients with systemic lupus erythematosus
por: Bertsias, G, et al.
Publicado: (2005)

Unlike PD-L1, PD-1 Is Downregulated on Partial Immune Cells in Type 2 Diabetes
por: Sun, Peng, et al.
Publicado: (2019)

Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis
por: Wang, Bing, et al.
Publicado: (2021)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis
por: Huang, Xin, et al.
Publicado: (2018)

Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer
por: Bari, Shahla, et al.
Publicado: (2019)

The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma
por: Xiao, Wen-jun, et al.
Publicado: (2019)

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
por: Au, Lewis, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis
por: Berntsson, Jonna, et al.
Publicado: (2018)

Programmed death 1 (PD‐1) and ligand (PD‐L1) inhibitors in head and neck squamous cell carcinoma: A meta‐analysis
por: Levy, Dylan A., et al.
Publicado: (2022)

Expression of Programmed Cell Death-1 (PD-1) and Its Ligand (PD-L1) in Breast Cancers and Its Association with Clinicopathological Parameters
por: Mehan, Anoushika, et al.
Publicado: (2021)

Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma
por: Lomphithak, Thanpisit, et al.
Publicado: (2021)

Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis
por: Liang, Jiaqi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2a1l0p36kl0vk8snf60lfsm3oe